The use of TNF-α blockers in psoriatic arthritis patients with latent tuberculosis infection

Clinical Rheumatology

Volumn 33, Issue 4, 2014, Pages 543-547

  Atteno, Mariangela ^a   Costa, Luisa ^a   Matarese, Alessandro ^a   Caso, Francesco ^b,c   Del Puente, Antonio ^a   Cantarini, Luca ^c   Bocchino, Maria Luisa ^a   Sanduzzi, Alessandro ^a   Scarpa, Raffaele ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b UNIVERSITY OF PADOVA   (Italy)

^c UNIVERSITY OF SIENA   (Italy)

Author keywords

Anti TNF ; IGRA; LTBI; PsA; TST; Tuberculosis

Indexed keywords

ADALIMUMAB; ETANERCEPT; INFLIXIMAB; ANTIRHEUMATIC AGENT; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; CONCURRENT INFECTION; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; LATENT TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PSORIATIC ARTHRITIS; RETROSPECTIVE STUDY; THORAX RADIOGRAPHY; UNSPECIFIED SIDE EFFECT; ANTAGONISTS AND INHIBITORS; ARTHRITIS, PSORIATIC; CASE CONTROL STUDY; IMMUNOLOGY; INTERFERON GAMMA RELEASE ASSAY; LUNG; MIDDLE AGED; RADIOGRAPHY; TREATMENT OUTCOME; TUBERCULIN TEST;

ADALIMUMAB; ADULT; ANTIRHEUMATIC AGENTS; ARTHRITIS, PSORIATIC; CASE-CONTROL STUDIES; ETANERCEPT; FEMALE; HUMANS; INFLIXIMAB; INTERFERON-GAMMA RELEASE TESTS; LATENT TUBERCULOSIS; LUNG; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; TUBERCULIN TEST; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84898840784     PISSN: 07703198     EISSN: 14349949     Source Type: Journal    
DOI: 10.1007/s10067-014-2536-z     Document Type: Article

References (26)

1. Moll JM, Wright V (1973) Psoriatic arthritis. Semin Arthritis Rheum 3:55-78
2. Tillett W, Costa L, Jadon D, Wallis D, Cavill C, McHugh J, Korendowych E, McHugh N (2012) The ClASsification for Psoriatic ARthritis (CASPAR) criteria - a retrospective feasibility, sensitivity, and specificity study. J Rheumatol 39:154-156
3. Soscia E, Sirignano C, Catalano O, Atteno M, Costa L, Caso F, Peluso R, Bruner V, Aquino MM, Del Puente A, Salvatore M, Scarpa R (2012) New developments in magnetic resonance imaging of the nail unit. J Rheumatol Suppl 89:49-53
4. Scarpa R, Manguso F, D'Arienzo A, D'Armiento FP, Astarita C, Mazzacca G, Ayala F (2000) Microscopic inflammatory changes in colon of patients with both active psoriasis and psoriatic arthritis without bowel symptoms. J Rheumatol 27:1241-1246
5. Costa L, Caso F, D'Elia L, Atteno M, Peluso R, Del Puente A, Strazzullo P, Scarpa R (2012) Psoriatic arthritis is associated with increased arterial stiffness in the absence of known cardiovascular risk factors: a case control study. Clin Rheumatol 31:711-715
6. Costa L, Caso F, Atteno M, Del Puente A, Darda MA, Caso P, Ortolan A, Fiocco U, Ramonda R, Punzi L, Scarpa R (2013) Impact of 24-month treatment with etanercept, adalimumab, or methotrexate on metabolic syndrome components in a cohort of 210 psoriatic arthritis patients. Clin Rheumatol. doi: 10.1007/s10067-013-2378-0
7. Atteno M, Peluso R, Costa L, Padula S, Iervolino S, Caso F, Sanduzzi A, Lubrano E, Del Puente A, Scarpa R (2010) Comparison of effectiveness and safety of infliximab, etanercept, and adalimumab in psoriatic arthritis patients who experienced an inadequate response to previous disease-modifying antirheumatic drugs. Clin Rheumatol 29:399-403
8. Scarpa R, Atteno M, Lubrano E, Provenzano G, D'Angelo S, Spadaro A, Costa L, Olivieri I (2011) The effectiveness and safety of TNF-alpha blockers in the treatment of early psoriatic arthritis: an Italian multicentre longitudinal observational pilot study. Clin Rheumatol 30:1063-1067
9. Fiocco U, Sfriso P, Oliviero F, Lunardi F, Calabrese F, Scagliori E, Cozzi L, Di Maggio A, Nardacchione R, Molena B, Felicetti M, Gazzola K, Stramare R, Rubaltelli L, Accordi B, Costa L, Roux-Lombard P, Punzi L, Dayer JM (2013) Blockade of intra-articular TNF in peripheral spondyloarthritis: its relevance to clinical scores, quantitative imaging and synovial fluid and synovial tissue biomarkers. Jt Bone Spine 80:165-170
10. Costa L, Caso F, Atteno M, Giannitti C, Spadaro A, Ramonda R, Vezzù M, Del Puente A, Morisco F, Fiocco U, Galeazzi M, Punzi L, Scarpa R (2014) Long-term safety of anti-TNF-α in PsA patients with concomitant HCV infection: a retrospective observational multicenter study on 15 patients. Clin Rheumatol 33:273-276
11. Bellofiore B, Matarese A, Balato N, Gaudiello F, Scarpa R, Atteno M, Bocchino M, Sanduzzi A (2009) Prevention of tuberculosis in patients taking tumor necrosis factor-alpha blockers. J Rheumatol Suppl 83:76-77
12. Dye C, Scheele S, Dolin P, Pathania V, Raviglione MC (1999) Consensus statement. Global burden of tuberculosis: estimated incidence, prevalence, and mortality by country. WHO Global Surveillance and Monitoring Project. JAMA 282:677-686
13. Kindler V, Sappino AP (1991) The beneficial effects of localized tumor necrosis factor production in BCG infection. Behring Inst Mitt 88:120-124
14. Suryaprasad AG, Prindiville T (2003) The biology of TNF blockade. Autoimmun Rev 2:346-357
15. Sanduzzi A, Bocchino M, Atteno M, Costa L, Ponticiello A, Matarese A, Spanò A, Bruner V, Peluso R, Aquino MM, Del Puente A, Scarpa R (2012) Screening and monitoring of latent tubercular infection in patients taking tumor necrosis factor-α blockers for psoriatic arthritis. J Rheumatol Suppl 89:82-85
16. Furst DE, Keystone EC, Fleischmann R, Mease P, Breedveld FC, Smolen JS, Kalden JR, Braun J, Bresnihan B, Burmester GR, De Benedetti F, Dörner T, Emery P, Gibofsky A, Kavanaugh A, Kirkham B, Schiff MH, Sieper J, Singer N, Van Riel PL, Weinblatt ME, Weisman MH, Winthrop K (2010) Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2009. Ann Rheum Dis 69(Suppl 1):i2-i29
17. Dixon WG, Watson K, Lunt M, Hyrich KL, Silman AJ, Symmons DP, British Society for Rheumatology Biologics Register (2006) Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 54:2368-76
18. Olleros ML, Guler R, Corazza N, Vesin D, Eugster HP, Marchal G, Chavarot P, Mueller C, Garcia I (2002) Transmembrane TNF induces an efficient cell-mediated immunity and resistance to Mycobacterium bovis bacillus Calmette-Guérin infection in the absence of secreted TNF and lymphotoxin-alpha. J Immunol 168:3394-3401
19. Gómez-Reino JJ, Carmona L, Valverde VR, Mola EM, Montero MD, BIOBADASER Group (2003) Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report. Arthritis Rheum 48:2122-7
20. Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD, Siegel JN, Braun MM (2001) Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 345:1098-1104
21. Keane J (2005) TNF-blocking agents and tuberculosis: new drugs illuminate an old topic. Rheumatology (Oxford) 44:714-720
22. American Thoracic Society (2000) Targeted tuberculin testing and treatment of latent tuberculosis infection. MMWR Recomm Rep 49(RR-6):1-51
23. Gilroy SA, Gilroy SA, Rogers MA, Blair DC (2000) Treatment of latent tuberculosis infection in patients aged > or =35 years. Clin Infect Dis 31:826-829
24. Valls V, Ena J (2014) Short-course treatment of latent tuberculosis infection in patients with rheumatic conditions proposed for anti-TNF therapy. Clin Rheumatol. doi: 10.1007/s10067-014-2495-4
25. Tubach F, Salmon D, Ravaud P, Allanore Y, Goupille P, Bréban M, Pallot-Prades B, Pouplin S, Sacchi A, Chichemanian RM, Bretagne S, Emilie D, Lemann M, Lortholary O, Mariette X, Research Axed on Tolerance of Biotherapies Group (2009) Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: the three-year prospective French Research Axed on Tolerance of Biotherapies registry. Arthritis Rheum 60:1884-1894
26. Dixon WG, Hyrich KL, Watson KD, Lunt M, Galloway J, Ustianowski A, B S R B R Control Centre Consortium, Symmons DP, BSR Biologics Register (2010) Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR). Ann Rheum Dis 69:522-528